


Ask a doctor about a prescription for TELMISARTAN CINFA 40 mg TABLETS
Package Leaflet: Information for the Patient
telmisartan cinfa 40 mg tablets EFG
Read the package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet
Contents of the pack and further information
Telmisartan cinfa belongs to a class of medications known as angiotensin II receptor antagonists. Angiotensin II is a substance produced in your body that causes your blood vessels to narrow, increasing your blood pressure.
Telmisartan cinfa blocks the effect of angiotensin II, causing your blood vessels to relax and your blood pressure to decrease.
Telmisartan is used totreat essential hypertension (high blood pressure) in adults. "Essential" means that high blood pressure is not caused by any other condition.
High blood pressure, if left untreated, can damage blood vessels in various organs, which can lead to heart attacks, heart failure, or kidney failure, strokes, or blindness in some cases. Usually, there are no symptoms of high blood pressure before damage occurs. Therefore, it is essential to regularly check your blood pressure to see if it is within the normal range.
Telmisartan is also used toreduce cardiovascular events (e.g., heart attacks or strokes) in adults at risk because their blood supply to the heart or legs is reduced or blocked, or they have had a stroke or are at high risk of developing diabetes. Your doctor will inform you if you are at high risk of experiencing these events.
Do not take telmisartan cinfa
If your case is any of the above, inform your doctor or pharmacist before taking telmisartan.
Warnings and precautions
Consult your doctor or pharmacist before starting to take telmisartan cinfa if you are suffering or have ever suffered from any of the following disorders or diseases:
Consult your doctor before starting to take telmisartan.
Your doctor may monitor your kidney function, blood pressure, and blood electrolyte levels (e.g., potassium) at regular intervals. See also the information under the heading "Do not take telmisartan cinfa" and "Warnings and precautions".
Consult your doctor if you experience abdominal pain, nausea, vomiting, or diarrhea after taking telmisartan. Your doctor will decide whether to continue treatment. Do not stop taking telmisartan on your own.
If you are pregnant, think you may be pregnant, or plan to become pregnant, inform your doctor. Telmisartan is not recommended at the start of pregnancy (first 3 months) and should not be taken after the third month of pregnancy, as it may cause serious harm to your baby, see the Pregnancy section.
In case of surgery or anesthesia, inform your doctor that you are taking telmisartan.
Telmisartan may be less effective in lowering blood pressure in black patients.
Children and adolescents
The use of telmisartan is not recommended in children and adolescents up to 18 years.
Taking telmisartan cinfa with other medications
Inform your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication. Your doctor may need to change the dose of these medications or take other precautions. In some cases, you may need to stop taking one of the medications. This is especially applicable to the following medications when taken with telmisartan:
The effect of telmisartan may be reduced when you use NSAIDs (non-steroidal anti-inflammatory drugs, e.g., aspirin or ibuprofen) or corticosteroids.
Telmisartan may increase the blood pressure-lowering effect of other medications used to treat high blood pressure or medications that may potentially lower blood pressure (e.g., baclofen, amifostine).
Additionally, the decrease in blood pressure may be exacerbated by alcohol, barbiturates, narcotics, or antidepressants. You may notice this effect as dizziness when standing up. You should consult your doctor if you need to adjust the dose of your other medications while taking telmisartan.
Pregnancy and breastfeeding
If you are pregnant, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy
You should inform your doctor if you are pregnant, think you may be pregnant, or plan to become pregnant. In general, your doctor will advise you to stop taking telmisartan before becoming pregnant or as soon as you become pregnant and recommend taking another blood pressure medication instead. Telmisartan is not recommended at the start of pregnancy and should not be taken after the third month of pregnancy, as it may cause serious harm to your baby when taken from that time on.
Breastfeeding
Inform your doctor if you are about to start or are breastfeeding, as telmisartan is not recommended for women during this period. Your doctor may decide to administer a treatment that is more suitable if you want to breastfeed, especially newborns or premature babies.
Driving and using machines
Some people may feel dizzy or tired when taking telmisartan. If you feel dizzy or tired, do not drive or use machines.
telmisartan cinfa contains lactose
This medication contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
telmisartan cinfa contains sodium
This medication contains less than 23 mg of sodium (1 mmol) per tablet; this is, essentially "sodium-free".
Follow the instructions for administration of this medication exactly as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
The recommended dose is one tablet per day. Try to take the tablet at the same time each day. You can take telmisartan with or without food. The tablets should be swallowed with a little water or other non-alcoholic beverage. It is essential that you take telmisartan every day until your doctor tells you to stop. If you think the effect of telmisartan is too strong or too weak, tell your doctor or pharmacist.
The tablet can be divided into two equal doses.
For the treatment of high blood pressure, the usual dose of telmisartan for most patients is one 40 mg tablet once daily, to control blood pressure over 24 hours. However, your doctor may sometimes recommend a lower dose of 20 mg or a higher dose of 80 mg. Telmisartan can also be used in combination with diuretics, such as hydrochlorothiazide, which has been shown to have an additive blood pressure-lowering effect with telmisartan.
For the reduction of cardiovascular events, the recommended daily dose of telmisartan is one 80 mg tablet. At the start of preventive treatment with telmisartan 80 mg, blood pressure should be monitored frequently.
If your liver is not functioning correctly, the usual dose should not exceed 40 mg once daily.
If you take more telmisartan cinfa than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take telmisartan cinfa
If you forget to take a dose, do not worry. Take it as soon as you remember and continue as before. If you do not take your tablet one day, take your normal dose the next day. Do nottake a double dose to make up for forgotten doses.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone gets them.
Some side effects can be serious and require immediate medical attention
If you experience any of the following symptoms, you should see your doctor immediately:
Sepsis* (often called "blood infection", a severe infection that involves an inflammatory reaction of the whole body), rapid swelling of the skin and mucous membranes (angioedema); these side effects are rare (may affect up to 1 in 1,000 people) but are extremely serious, and patients should stop taking the medication and see their doctor immediately. If these side effects are not treated, they can be fatal.
Possible side effects of telmisartan
Common side effects (may affect up to 1 in 10 people)
Low blood pressure (hypotension) in users treated for cardiovascular event reduction.
Uncommon side effects (may affect up to 1 in 100 people)
Urinary tract infections, upper respiratory tract infections (e.g., sore throat, sinusitis, common cold), decreased red blood cells (anemia), high potassium levels, difficulty falling asleep (insomnia), feeling sad (depression), fainting (syncope), feeling of loss of balance (vertigo), slow heart rate (bradycardia), low blood pressure (hypotension) in users treated for high blood pressure, dizziness when standing up (orthostatic hypotension), difficulty breathing, cough, abdominal pain, diarrhea, abdominal discomfort, abdominal distension, vomiting, itching, increased sweating, drug rash (skin reaction to medications), back pain, muscle cramps, muscle pain (myalgia), kidney failure including acute kidney failure, chest pain, symptoms of weakness, and high creatinine levels in the blood.
Rare side effects (may affect up to 1 in 1,000 people)
Sepsis* (often called "blood infection", a severe infection that involves an inflammatory reaction of the whole body and can cause death), increased certain white blood cells (eosinophilia), low platelet count (thrombocytopenia), severe allergic reaction (anaphylactic reaction), allergic reaction (e.g., rash, itching, difficulty breathing, wheezing, swelling of the face or low blood pressure), low blood sugar levels (in diabetic patients), feeling anxious, drowsiness, vision changes, increased heart rate (tachycardia), dry mouth, stomach upset, taste disturbances (dysgeusia), abnormal liver function (Japanese patients show a greater tendency to experience this side effect), sudden swelling of the skin and mucous membranes that can cause death (angioedema, including fatal outcome), eczema (a skin condition), redness of the skin, hives (urticaria), severe drug rash, joint pain (arthralgia), pain in the limbs, pain in the tendons, pseudogripal illness, decrease in hemoglobin (a blood protein), increased blood levels of uric acid, increased liver enzymes or creatine phosphokinase in the blood.
Very rare side effects (may affect up to 1 in 10,000 people) Progressive fibrosis of lung tissue (interstitial lung disease)**.
Side effects of unknown frequency: Intestinal angioedema: inflammation in the intestine with symptoms such as abdominal pain, nausea, vomiting, and diarrhea has been reported after the use of similar products.
** Cases of progressive fibrosis of lung tissue have been reported during the use of telmisartan. However, it is unknown whether telmisartan was the cause.
Reporting side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. You can also report them directly through the Spanish Medicines and Healthcare Products Agency (AEMPS) website: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date stated on the packaging after EXP. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medications should not be disposed of via wastewater or household waste. Dispose of the packaging and any unused medication at the pharmacy's SIGRE collection point. If in doubt, ask your pharmacist how to dispose of the packaging and any unused medication. This will help protect the environment.
Composition of telmisartan cinfa
Appearance of the product and packaging
telmisartan cinfa 40 mg are white, cylindrical, biconvex, scored, and marked with the code "T40" tablets.
They are available in aluminum/aluminum blisters.
Each pack contains 28 or 98 (clinical pack) tablets.
Not all pack sizes may be marketed.
Marketing authorization holder and manufacturer
Laboratorios Cinfa, S.A.
Carretera Olaz-Chipi, 10. Polígono Industrial Areta
31620 Huarte (Navarra) - Spain
Date of last revision of this package leaflet:February 2025
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Healthcare Products (AEMPS) http://www.aemps.gob.es
You can access detailed and updated information about this medication by scanning the QR code included in the package leaflet and packaging with your smartphone. You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/77605/P_77605.html
QR code to: https://cima.aemps.es/cima/dochtml/p/77605/P_77605.html
The average price of TELMISARTAN CINFA 40 mg TABLETS in November, 2025 is around 9.99 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for TELMISARTAN CINFA 40 mg TABLETS – subject to medical assessment and local rules.